Vontobel Holding Ltd. Sells 9,261 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Vontobel Holding Ltd. decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 53,309 shares of the medical research company’s stock after selling 9,261 shares during the quarter. Vontobel Holding Ltd.’s holdings in IQVIA were worth $10,476,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in IQVIA during the 3rd quarter valued at $27,000. Avior Wealth Management LLC raised its holdings in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the period. Synergy Asset Management LLC bought a new stake in IQVIA during the 4th quarter valued at $33,000. Assetmark Inc. raised its holdings in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the period. Finally, Concord Wealth Partners bought a new stake in IQVIA during the 3rd quarter valued at $57,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Morgan Stanley boosted their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Leerink Partners restated an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.67.

IQVIA Stock Performance

IQVIA stock opened at $193.65 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $35.15 billion, a PE ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48. The firm has a fifty day simple moving average of $200.59 and a two-hundred day simple moving average of $218.51. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Insider Activity

In other news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.